These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 30912613)
1. Peripheral blood test provides a practical method for glioma evaluation and prognosis prediction. Wang ZL; Zhang CB; Liu YQ; Wang Z; Jiang T CNS Neurosci Ther; 2019 Aug; 25(8):876-883. PubMed ID: 30912613 [TBL] [Abstract][Full Text] [Related]
2. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas. Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441 [TBL] [Abstract][Full Text] [Related]
3. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion. Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154 [TBL] [Abstract][Full Text] [Related]
4. Preoperative Neutrophil/Lymphocyte Ratio Is an Independent Prognostic Biomarker in Patients with Low-Grade Gliomas. Tan Z; Shen L; Wu H; Deng L; Li Z; Huang X World Neurosurg; 2019 Dec; 132():e585-e590. PubMed ID: 31442642 [TBL] [Abstract][Full Text] [Related]
5. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation. Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593 [TBL] [Abstract][Full Text] [Related]
6. Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference. Zhang C; Li J; Wang H; Song SW Oncotarget; 2016 Nov; 7(45):73971-73983. PubMed ID: 27738332 [TBL] [Abstract][Full Text] [Related]
7. Molecular subtyping reveals immune alterations in IDH wild-type lower-grade diffuse glioma. Wu F; Li GZ; Liu HJ; Zhao Z; Chai RC; Liu YQ; Jiang HY; Zhai Y; Feng YM; Li RP; Zhang W J Pathol; 2020 Jul; 251(3):272-283. PubMed ID: 32418210 [TBL] [Abstract][Full Text] [Related]
8. Intratumoral Susceptibility Signals Reflect Biomarker Status in Gliomas. Kong LW; Chen J; Zhao H; Yao K; Fang SY; Wang Z; Wang YY; Li SW Sci Rep; 2019 Nov; 9(1):17080. PubMed ID: 31745161 [TBL] [Abstract][Full Text] [Related]
9. Amide proton transfer imaging might predict survival and IDH mutation status in high-grade glioma. Joo B; Han K; Ahn SS; Choi YS; Chang JH; Kang SG; Kim SH; Zhou J; Lee SK Eur Radiol; 2019 Dec; 29(12):6643-6652. PubMed ID: 31175415 [TBL] [Abstract][Full Text] [Related]
10. Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas. Chen R; Ravindra VM; Cohen AL; Jensen RL; Salzman KL; Prescot AP; Colman H Neurosurg Focus; 2015 Mar; 38(3):E2. PubMed ID: 25727224 [TBL] [Abstract][Full Text] [Related]
11. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas. Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009 [TBL] [Abstract][Full Text] [Related]
12. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas. Zhang J; Yang JH; Quan J; Kang X; Wang HJ; Dai PG Tumour Biol; 2016 Oct; 37(10):13571-13579. PubMed ID: 27468718 [TBL] [Abstract][Full Text] [Related]
13. Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas. Li MY; Wang YY; Cai JQ; Zhang CB; Wang KY; Cheng W; Liu YW; Zhang W; Jiang T PLoS One; 2015; 10(6):e0130872. PubMed ID: 26115094 [TBL] [Abstract][Full Text] [Related]
14. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864 [TBL] [Abstract][Full Text] [Related]
15. Neutrophil/Lymphocyte Ratio Is an Independent Prognostic Factor in Elderly Patients with High-Grade Gliomas. Gan Y; Zhou X; Niu X; Li J; Wang T; Zhang H; Yang Y; Liu Y; Mao Q World Neurosurg; 2019 Jul; 127():e261-e267. PubMed ID: 30898756 [TBL] [Abstract][Full Text] [Related]
16. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas. Yoo RE; Yun TJ; Hwang I; Hong EK; Kang KM; Choi SH; Park CK; Won JK; Kim JH; Sohn CH Eur Radiol; 2020 Feb; 30(2):1202-1211. PubMed ID: 31468161 [TBL] [Abstract][Full Text] [Related]
17. Clinical and Molecular Recursive Partitioning Analysis of High-grade Glioma Treated With IMRT. Sutera P; Kalash R; Flickinger J; Engh J; Heron DE Am J Clin Oncol; 2019 Jan; 42(1):27-35. PubMed ID: 29912004 [TBL] [Abstract][Full Text] [Related]
18. Use of statins or NSAIDs and survival of patients with high-grade glioma. Seliger C; Schaertl J; Gerken M; Luber C; Proescholdt M; Riemenschneider MJ; Leitzmann MF; Hau P; Klinkhammer-Schalke M PLoS One; 2018; 13(12):e0207858. PubMed ID: 30507932 [TBL] [Abstract][Full Text] [Related]
19. Single-copy gain of chromosome 1q is a negative prognostic marker in pediatric nonependymal, nonpilocytic gliomas. Miwa T; Hirose Y; Sasaki H; Ezaki T; Yoshida K; Kawase T Neurosurgery; 2011 Jan; 68(1):206-12. PubMed ID: 21099717 [TBL] [Abstract][Full Text] [Related]
20. Expression and prognostic value of mRNAs in lower grade glioma with MGMT promoter methylated. Wang W; Li J; Lin F; Guo J; Zhao J J Clin Neurosci; 2020 May; 75():45-51. PubMed ID: 32229069 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]